Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient settingGuglieri-López, Beatriza; Pérez-Pitarch, Alejandrob; Porta-Oltra, Begoñaa; Ferriols-Lisart, Franciscob; Climente-Martí, Mónicaa; Alós-Almiñana, ManuelbAnti-Cancer Drugs: September 2015 - Volume 26 - Issue 8 - p 860–865 doi: 10.1097/CAD.0000000000000240 CLINICAL REPORTS Buy Abstract Author InformationAuthors Article MetricsMetrics The aim of this study was to evaluate the effectiveness and toxicity profile of the vinflunine chemotherapy regimen and to examine the cost-effectiveness relation in a real-world sample of patients with transitional cell carcinoma of the bladder. This is a multicenter, observational, retrospective cohort study. To assess the effectiveness and safety of vinflunine treatment, progression-free survival, overall survival, and adverse events were registered. An economic evaluation was performed and cost-effectiveness ratios were calculated. A total of 37 patients were included in the study, with a mean age of 67 (SD=9) years. The median progression-free survival was 2.61 months (95% confidence interval 1.79–4.23) and the median overall survival was 5.72 months (95% confidence interval 3.34–10.35). An objective response was achieved in eight (22%) patients. Statistically significant differences were found between patients treated with vinflunine as a second-line therapy and those treated with vinflunine as a third-line therapy (P=0.036). The most commonly reported analytical adverse event was anemia (n=34; 92%), and the most severe was neutropenia (n=19; 51%), with nine patients developing grade 4 neutropenia (9/19; 47%). The total cost of vinflunine treatment was €553 873, with a median of €8524 (interquartile range, €9220) per patient. The median-based cost-effectiveness ratio was €44 789 (€31 706–58 022) per progression-free year gained and €22 750 (€14 526–34 085) per life-year gained. The data from this study fill an important need for information on the relative value of this treatment in terms of cost-effectiveness and might help achieve an optimal quality healthcare system. aDepartment of Pharmacy, Doctor Peset University Hospital of Valencia bDepartment of Pharmacy, University Clinical Hospital of Valencia, Valencia, Spain Correspondence to Beatriz Guglieri-López, Gaspar Aguilar Avenue, 90, 46017, Valencia, Spain Tel: +34 961 622379; e-mail: firstname.lastname@example.org Received December 19, 2014 Accepted March 17, 2015 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.